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Acute Liver Failure Associated with Occupational Exposure  
to Tetrachloroethylene
Tetrachloroethylene is a chlorinated solvent that is primarily used in dry cleaning and 
degreasing operations. Although the hepatotoxicity caused by tetrachloroethylene has 
been well documented in literature, it is rarely considered as a cause of acute liver failure. 
We report a case of a 39-yr-old man who was admitted to our hospital for acute liver 
failure due to tetrachloroethylene exposure. Histological examination of the liver revealed 
massive hepatic necrosis, prominently, in zone 3 of the hepatic lobules. The patient 
underwent supportive treatment along with 3 sessions of plasmapheresis, and 
consequently, he presented a favorable outcome. Repeat liver biopsy performed 6 months 
after the patient’s discharge showed architectural distortion with postnecrotic cirrhosis. 
Physicians should be aware of the possibility of acute liver failure induced by 
tetrachloroethylene. Early plasmapheresis can be effective for individuals with sufficient 
capacity for hepatocyte regeneration.
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INTRODUCTION
Tetrachloroethylene or perchloroethylene (PCE), a common 
industrial solvent and environmental contaminant, is primarily 
used in the dry-cleaning industry, for metal degreasing opera-
tions, and in the textile industry (1, 2). It is also present in certain 
consumer products, including paint strippers, spot removers, 
silicone lubricants, and food (2). Studies have provided clear 
evidence that both acute and chronic exposure to PCE can cause 
numerous adverse effects. As in the cases of toxicity due to the 
exposure to other chlorinated solvents, the target organs for PCE 
toxicity in humans are the central nervous system, liver, and kid-
neys. The documented symptoms of toxicity due to the expo-
sure to PCE include headache, dizziness, fatigue, nausea, vom-
iting, pulmonary edema, and signs of impaired hepatic or renal 
function, depending on the level of PCE exposure (2-4). Severe 
exposure to PCE can induce behavior alteration, coma, and 
death (2, 4). In addition, PCE causes irritation in the eyes, nose, 
and upper respiratory tract (4). Moreover, the International Agen-
cy for Research on Cancer classified PCE as a potential human 
carcinogen (5). Although hepatotoxic effects have been report-
ed in humans after heavy exposure to PCE, acute liver failure 
has not been previously reported. 
  We report, for the first time, a case of successful treatment of 
PCE-induced acute liver failure with plasmapheresis. We also 
describe the pathological features of the condition on the basis 
of initial and repeat liver biopsies.
CASE DESCRIPTION
A 39-yr-old male patient was admitted to our liver intensive care 
unit (LICU) for acute liver failure on August 20, 2009. The patient 
worked at a leather-manufacturing plant, where he cleaned an-
imal coats by using PCE. The patient informed us that he occa-
sionally did not wear protective devices during this procedure 
and that the process room at the plant was poorly ventilated. 
After working for about 50 days, the patient suddenly began 
passing dark urine, but continued his regular work. During the 
next 4 days, the patient developed progressive jaundice with 
nausea, vomiting, loss of appetite, and weakness and was ad-
mitted to a local hospital. Blood chemistry revealed the follow-
ing findings: total bilirubin (TBIL), 202.8 μM/L (normal range, 
3.0-20.0 μM/L); alanine aminotransferase (ALT), 743 U/L (nor-
mal range, 5-40 U/L); alkaline phosphatase (ALP), 189 U/L (nor-
mal range, 15-130 U/L); and gamma glutamyl transferase (GGT), 
99 U/L (normal range, 12-58 U/L). Serum concentration of PCE 
was 2.8 mg/L and urinary concentration of trichloroacetic acid 
(TCA)-an indirect biomarker for PCE poisoning-was 8.4 mg/L. 
Treatment with hepatoprotective agents failed to achieve any 
remission. Further, the patient developed coagulopathy associ-
ated with progressive deterioration of liver function, which in 
turn led to the development of grade II hepatic encephalopathy 
within 48 hr. Therefore, he was transferred to our hospital. 
  The patient had no notable exposure to toxic chemicals be-
fore this job. He denied smoking or alcohol or drug use before Shen C, et al.  •  Liver Failure with Exposure to PCE
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the onset of the symptoms. The patient had not received blood 
transfusion; not traveled recently; had no family history of liver 
disease; and none of his colleagues had similar manifestations. 
On the day of admission to the LICU, all his vital signs were with-
in normal limits. Physical examination revealed grade II hepatic 
encephalopathy with confusion, slurred speech, asterixis, and 
disorientation for time and place. The patient had severe jaun-
dice, but without peripheral edema. The patient developed ec-
chymoses at the therapeutic puncture sites. The liver, spleen, 
and kidneys were not palpable. Abdominal or costovertebral 
angle tenderness was not detected. 
  Laboratory examinations performed at the time of admission 
showed the following biochemical results: ALT, 1,100 U/L; as-
partate aminotransferase (AST), 355 U/L (normal range, 10-40 
U/L); TBIL, 421.8 µM/L; direct serum bilirubin (DBIL), 197.3 
µM/L (normal range, 0.0-7.0 µM/L); ALP, 201 U/L; GGT, 139 U/L; 
prothrombin time (PT) 51.0 s (normal range, 9.0-12.8 s); inter-
national normalized ratio (INR), 3.32 (normal range, 0.8-1.4); 
ammonia, 151 μM/L (normal range, 9-33 μM/L); alfa-fetopro-
tein (AFP), 1,045 ng/mL (normal range, 0-9 ng/mL); and normal 
electrolyte, hematological, and renal functions. Peripheral T-lym-
phocyte subpopulations, analyzed by flow cytometry, showed 
CD4/CD8 ratio of 3.74 (normal range, 1.33-1.99). Serological 
studies for viral hepatitis (hepatitis A, B, C, D, and E viruses; hu-
man immunodeficiency virus; Epstein–Barr virus; cytomegalo-
virus) and autoimmunity markers (antinuclear, antimitochon-
drial, antineutrophil cytoplasmic, anti-smooth-muscle, and anti-
liver-kidney microsome antibodies) were negative. Screening 
studies were performed to detect genetic and metabolic liver 
diseases and hematochromatosis, Wilson’s disease, and alpha 
1-antitrypsin deficiency were excluded. Doppler ultrasonogra-
phy of the patient’s abdomen revealed homogeneous echogenic 
liver that had decreased in size; had patent portal veins, hepatic 
artery, and hepatic veins; and no obstruction of the biliary tracts. 
The spleen appeared normal, and no ascites was observed.
  The patient was managed with general supportive care along 
with intravenous administration of dexamethasone (15 mg dai-
ly) for 5 consecutive days. He was also treated with liver-protec-
tive preparations, glutathione, ademetionine, hepatocyte growth-
promoting factors, and prophylactic antibiotics. Furthermore, 
plasmapheresis was performed on days 1, 3, and 5, with 3,000 
mL of plasma exchanged during each session. Gradually, the 
patient’s mental status became normal, and liver function, co-
agulation profiles and other biochemical variables improved 
notably (Fig. 1). The maximum AFP level was 3,000 ng/mL. The 
patient underwent percutaneous liver biopsy on day 12; the bi-
opsy revealed massive hepatocellular necrosis prominently in 
the centrilobular area with moderate inflammatory infiltration 
mainly of lymphocytes and neutrophils. We also detected dif-
fuse swelling of the hepatocytes and hemorrhagic infiltration in 
some necrotic areas. Neither obvious expansion of portal vein 
nor increased deposition of fibrous tissue was detected. Bile 
ducts appeared normal except for cholangioles with bile plugs 
(Fig. 2). The pathological features indicated drug-induced acute 
liver injury. The patient responded well to treatment, and grad-
ually, his general condition improved and all symptoms even-
tually resolved except for poor appetite and fatigue. The patient 
was discharged from the hospital on day 26 and advised to com-
pletely avoid exposure to PCE at his workplace.
  The patient underwent regular follow-up every month, and 
liver function and AFP level became normal after 2 months. 
Repeat liver biopsy performed 6 months after discharge showed 
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Fig. 1. Levels of biochemical parameters during hospitalization.Shen C, et al.  •  Liver Failure with Exposure to PCE
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fibrous expansion of the portal tracts caused by moderate in-
flammatory infiltration and nodular regeneration of the hepatic 
parenchyma delimited by thin fibrous bands and septa. The bi-
opsy showed evidence of some swollen hepatocytes and scat-
tered foci of hepatocellular necrosis within the liver lobules (Fig. 
3). Currently, the patient is  undergoing anti-liver fibrosis thera-
py using modern Chinese medicine (Fuzhenghuayu capsule) 
(6) and continues to receive follow-up.
DISCUSSION
PCE is mainly absorbed by mammals following inhalation and, 
to a lesser extent, by ingestion and dermal exposure (2, 4). PCE 
is highly soluble in adipose tissues. Most of the absorbed PCE 
(80%-90%) is excreted unchanged in expired air, regardless of 
the route of exposure, whereas only a small proportion (1%-3%) 
is metabolized to TCA, trichloroethanol, and trichloroacetyl 
chloride, which were subsequently eliminated in urine (2, 7). 
The serum half-life of PCE is estimated at 65 hr, and that of uri-
nary TCA at 144 hr (8, 9). Biotransformation of PCE occurs pre-
dominantly in the liver via cytochrome P-450 (CYP) oxidation 
pathway, which accounts for the highest percentage of metabo-
lites (2). Glutathione conjugation pathway, though a minor 
route, is activated when CYP oxidation is saturated (2, 10).
  The mechanism of PCE-induced hepatotoxicity has not yet 
been well elucidated. There is evidence that TCA, the principal 
metabolite of PCE, derived from CYP pathway may mainly con-
tribute to hepatotoxicity via several modes of action, including 
oxidative stress, mitochondrial dysfunction, and DNA damage 
(11). Few studies have indicated that PCE may exert suppres-
sive effects on the immune system (12). However, our patient 
showed a remarkably high CD4/CD8 ratio at the initial presen-
tation, indicating the possibility of a PCE-triggered cell-mediat-
ed immune response that might induce hepatocellular damage. 
In addition, the hepatic injury in our patient was more severe 
than those reported in patients in previous studies, and no ab-
normalities were detected in his colleagues who were exposed 
to the same conditions at work. We postulated that these differ-
A B
Fig. 2. Initial liver biopsy performed on day 12 of hospitalization. (A) Massive hepatocellular necrosis was mainly located in zone 3 with moderately inflammatory infiltration 
(Hematoxylin and eosin staining × 200). (B) No obvious deposition of fibrous tissue observed within portal tracts (Masson’s trichrome staining × 100).
A B
Fig. 3. Repeat liver biopsy performed 6 months after discharge. (A) Distortion of lobular structure of the liver accompanied by scattered foci of hepatocellular necrosis within 
lobules and lymphocytic piecemeal necrosis (Hematoxylin and eosin staining × 200). (B) Expanded portal tracts with fibrous septa indicative of postnecrotic hepatic cirrhosis 
(Masson’s trichrome staining × 200).Shen C, et al.  •  Liver Failure with Exposure to PCE
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ences may be attributable to genetic polymorphism in metabo-
lizing enzymes, which might lead to variations among the level 
of susceptibility of individual to PCE toxicity (11). Other factors 
such as age, sex, pattern of activity, health status, and alcohol 
consumption also influence PCE metabolism and toxicity.
  Several studies have reported PCE-induced hepatic abnor-
malities in patients. Meckler et al. (13) reported hepatocellular 
injury detected by liver biopsy in a woman with acute hepatitis 
after exposure to PCE. Bagnell et al. (14) reported a case of an 
infant presenting with obstructive jaundice and hepatomegaly 
due to PCE exposure via breast milk. Brodkin et al. (15) report-
ed hepatic ultrasonography findings showing diffuse parenchy-
mal changes in dry cleaners in comparison with ultrasonogra-
phy findings in control subjects. Liver damage in the form of 
hepatomegaly, jaundice, and elevation in levels of several he-
patic transaminases and bilirubin has also been reported. In 
most cases, hepatotoxicity was transient, and its effects were 
spontaneously resolved when exposure to PCE ended. Thus far, 
no study has reported acute liver failure associated with PCE 
exposure.
  Initially, the patient’s condition was similar to viral hepatitis 
and rapidly deteriorated, resulting in marked liver dysfunction, 
coagulopathy, and encephalopathy. On the basis of the patient’s 
occupational history, clinical manifestations, laboratory data, 
and liver biopsy findings, acute liver failure was attributable to 
occupational exposure to PCE, after other liver diseases had been 
completely excluded. We also assessed the patient using Maria 
and Victorino’s clinical diagnostic scale for drug-induced liver 
injury, and on the basis of his score 14, he was judged “proba-
ble” (16). Liver injuries caused by drugs are classified as three 
types: hepatocellular, cholestatic, and mixed injury (17). Our 
case presented with notably increased ALT level of 1,100 U/L 
and an ALT/ALP ratio more than 5, suggesting a hepatocellular 
injury pattern.
  Treatment for PCE-induced hepatotoxicity requires support-
ive care with close monitoring to prevent associated toxicities 
to other systemic organs. Our patient developed acute liver fail-
ure, which was a rare medical condition associated with high 
mortality. On the basis of Model for End-Stage Liver Disease 
(MELD) score of 30, the patient was a candidate for living-relat-
ed orthotropic liver transplantation (18). However, the opera-
tion was postponed owing to shortage of donors. Plasmaphere-
sis has been successfully used in management of acute or chron-
ic liver failure, and it serves a treatment modality to achieve re-
covery of native liver function or until an appropriate donor is 
available. Although plasmapheresis has no established effects 
on elimination of serum PCE due to its relatively small molecu-
lar weight and short half time, it is an effective approach for re-
moving various endogenous toxins and immune complexes 
from systemic circulation, decreasing serum aminotransferase 
level, and improving the encephalopathy stage and coagulation 
profiles (19). All these effects of plasmapheresis may create a 
better internal environment for native hepatocyte regeneration 
and change the final outcomes in liver failure. Our patient may 
have benefited from plasmapheresis, as was evident by the no-
table improvement of clinical status and liver function. Due to 
the adjuvant evidence of increase in the CD4/CD8 ratio, steroids 
were administered to control immune-mediated liver damage. 
Indeed, his survival can be mainly attributed to the sufficient 
residual hepatic capacity for regeneration, as evidenced by the 
short-term dramatically high levels of serum AFP, with maxi-
mum value being more than 150 times greater than the normal 
range. 
  Initial biopsy revealed massive hepatic necrosis, primarily, in 
zone 3, which was consistent with the fact that hepatocytes in 
zone 3 were probably more susceptible to chemical-induced 
hepatotoxicity owing to the high concentration of CYP in these 
cells. Furthermore, although his liver function test revealed per-
sistently normal results for approximately 4 months, repeat bi-
opsy revealed foci of hepatocellular necrosis and lymphocytic 
piecemeal necrosis with inflammatory infiltration. Therefore, 
since liver function test cannot completely reflect the severity of 
liver injury and may give a falsely optimistic suggestion, liver 
biopsy is a better approach to assess the prognosis of liver dis-
ease. Our patient’s liver histology examination also showed typ-
ical postnecrotic cirrhosis, which was a result of active repair 
following massive hepatic necrosis. 
  Liver cirrhosis, in fact, is a rare sequel to drug-induced acute 
hepatitis, but it may occur if liver disease progresses to active 
chronic hepatitis, in which long-term liver lesions maintain. 
Moreover, a single episode of sufficiently severe injury, such as 
massive/submassive hepatic necrosis, can also cause liver cir-
rhosis due to collapse of lobular architecture and irregularly 
scarred repair. A rapid progression from severe hepatitis to cir-
rhosis, which is similar to that seen in our patient, has been doc-
umented in ebrotidine-induced liver injury with serial biopsy 
confirmation (20). 
  In conclusion, physicians should enhance their awareness of 
the possibility of acute liver failure induced by PCE exposure. 
Increased awareness and early diagnosis of the exposure to tox-
ic substances are essential for performing prompt management,    
improving clinical outcomes. In addition, early plasmapheresis 
can serve as a useful treatment approach for patients with PCE-
induced acute liver failure, particularly for those with sufficient 
hepatic capacity for hepatocyte regeneration.
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